ISSN: 2381-8727

International Journal of Inflammation, Cancer and Integrative Therapy
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Research Article   
  • Int J Inflam Cancer Integr Ther 2022, Vol 9(3): 192
  • DOI: 10.4172/2381-8727.1000192

Validation of Khorana Risk Score (KRS) in Cancer Patients: An Experience from a Tertiary Care Cancer Centre

Anadil Faqah1*, Hassan Sheikh2, Muhammad Abubakar2, Fatima Tayyaab3 and Sahrish Khawaja3
1Consultant Hospitalist, Diplomate American Board of Internal Medicine, Shaukat Khanam Memorial Cancer Hospital, Johar Town, Lahore, Pakistan
2Department of Oncology, Shaukat Khanam Memorial Cancer Hospital, Lahore, Pakistan
3Department of Internal Medicine, Shaukat Khanum Memorial Cancer Hospital, Lahore, Pakistan
*Corresponding Author : Anadil Faqah, Consultant Hospitalist, Diplomate American Board of Internal Medicine, Shaukat Khanam Memorial Cancer Hospital, Johar Town, Lahore, Pakistan, Email: anadilfaqah@skm.org.pk

Received Date: May 20, 2022 / Accepted Date: Jun 18, 2022 / Published Date: Jun 20, 2022

Abstract

Purpose: Venous Thromboembolism is a common and frequent complication seen in active cancer patients. The Khorana Risk Score (KRS) is a simple model which helps to guide selection of high risk VTE cancer patients for thromboprophylaxis. However very little information is available on Khorana score validation in low middle incomecountries; hence we aimed to evaluate its performance.

Patients and methods: A retrospective single center study utilizing data of 150 cancer patients with either symptomatic deep venous thrombosis (DVT) and/or pulmonary embolism (PE) from January 1, 2012 to Dec 31, 2017.The primary efficacy outcome was to validate Khorana Risk Score in our population.

Results: Overall, 32.7% of these patients had a low Khorana Risk Score of 0 point, 48% of patients had intermediate KRS of 1 or 2 points, and only 19.3% of patients had a high KRS of 3 or more points. We also looked at additional variables i.e. mean difference in albumin (g/dL) in the three Khorana Risk Score category which was statistically significant i.e. 3.88 g/dL ± 0.52 in low risk, 3.58 g/dL ± 0.65 in intermediate risk and 3.15 g/dL ± 0.85 in high risk [p<0.001]. Similarly the mean age difference was also significantly different in intermediate and high risk. We also looked at metastasis status, chemotherapy status and creatinine clearance in these patients but found they were statistically insignificant.

Summary: Our study showed that Khorana Risk Score tool was only able to risk stratify 19.3% of cancer patients in high risk category who would have benefitted from thromboprophylaxis. We recommend the development of a modified risk prediction model best adapted to local needs.

Citation: Faqah A, Sheikh H, Abubakar M, Tayyaab F, Khawaja S (2022) Validation of Khorana Risk Score (KRS) in Cancer Patients: An Experience from a Tertiary Care Cancer Centre. Int J Inflam Cancer Integr Ther, 9: 192. Doi: 10.4172/2381-8727.1000192

Copyright: © 2022 Faqah A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Top